ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET

ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET

BAUDETTE, Minn., Oct. 25, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2023 financial results on Wednesday, November 8, 2023, prior to the market open.

Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:

Date Wednesday, November 8, 2023
   
Time 8:30 a.m. ET
   
Toll free (U.S.) 800-445-7795
   
Webcast (live and replay) , under the “Investors” section
   

A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-839-6737 and entering access code 4379958.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through successful launch of our lead asset, Purified Cortrophin® Gel, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website .

Investor Relations Contact:

Lisa M. Wilson, In-Site Communications, Inc.

212-452-2793

SOURCE: ANI Pharmaceuticals, Inc.



EN
25/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANI Pharmaceuticals Inc.

 PRESS RELEASE

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual B...

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows: Date:Tuesday, May 20, 2025  Time:1:30pm ET  Webcast:   To schedule a 1x1 meeting with management, please contact The live and archived webcast will be accessible from the...

 PRESS RELEASE

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Result...

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 million Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% yea...

 PRESS RELEASE

ANI Pharmaceuticals Announces Presentation of Preclinical Data on the ...

ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced preclinical data on the use of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model. “In a...

 PRESS RELEASE

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on...

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows...

 PRESS RELEASE

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmolo...

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference as follows:   Date:Thursday, April 3, 2025Time:7:45am ETWebcast:   The live and archived webcast will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The replay...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch